TI
OVID icon

Trexquant Investment’s Ovid Therapeutics OVID Stock Holding History

Trexquant Investment’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,242
Closed -$87K – 1123
2018
Q1 		$87K Buy
+12,242
New +$99K 0.01% 1019

Other funds holding OVID

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Trexquant Investment's OVID Position: Q2 2018 in Review

Trexquant Investment sold out of Ovid Therapeutics (OVID) in Q2 2018, closing a stake of 12,242 shares — an estimated $87K sold.

Trexquant Investment first reported a position in OVID in Q1 2018 and held it in 1 quarter. The position peaked at $87K in Q1 2018. 48 funds tracked by Wall St. Rank hold OVID as of Q2 2018.

  • Trexquant Investment reported no remaining Ovid Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Trexquant Investment sold 12,242 Ovid Therapeutics shares in Q2 2018, an estimated $87K.
  • Trexquant Investment first reported a position in Ovid Therapeutics in Q1 2018 and held it in 1 quarter.
  • Trexquant Investment's Ovid Therapeutics position peaked at $87K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2018.

Based on Trexquant Investment's 13F filing for Q2 2018, filed 7 Aug 2018.